search
Back to results

TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management (REVAPRO)

Primary Purpose

Benign Prostatic Hyperplasia

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
TURP
PVP
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Benign Prostatic Hyperplasia focused on measuring Surgery, Prostate, Laser 532 nm, Photo selective Vaporization of the Prostate (PVP), TransUrethral Resection of the Prostate (TURP), Men health

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male, 50 years of age or older.
  2. American Society of Anesthesiology (ASA) classification of physical status, class 1-3
  3. Signed an informed consent at the beginning of the study.
  4. Patients presenting with LUTS associated to benign prostatic enlargement for more than 3 months, needing a surgical management, with at least one of the following situations: disability score ≥3, I-PSS ≥12, or full urinary retention
  5. Qmax ≤12ml /s for no drained patients with voided volume> 125 ml.
  6. Estimated prostate weight between 25g and 80g
  7. Patient free of catheter with PVR ≤ 300cc
  8. Patient without renal disorders.
  9. No prostate cancer suspicion at clinical examination, including DRE.
  10. PSA ≤ 10 ng/ml, with negative prostate biopsies of PSA is between 4 and 10 ng/mL if patient is 75 years or younger or has a life expectancy of more than 10 years.
  11. In case of anticoagulation or anti-aggregation therapy, necessary preoperative visit by anaesthesiologist to determine the supply therapy around surgery.
  12. In case of current BPH medical management, alpha blockers and herbal medicines should be stopped one week before surgery and 5-alpha-reductase-inhibitors should be stopped one month before surgery.
  13. Patient must be affiliated to the French social healthcare or equivalent

Exclusion Criteria:

  1. Uncontrolled cardiopulmonary disorder, previously or recently diagnosed by standard methods
  2. Assessed sphincter detrusor dyssynergia, or myasthenia, multiple sclerosis, or Parkinson disease.
  3. History of pelvic lesions with abdominal sphincter injury.
  4. Urinary tract infection without antibiotics.
  5. Patient with urinary catheter or suprapubic catheter because of an acute urinary retention linked to an alternative diagnosis or impaired bladder sensation.
  6. Subject with neurogenic bladder and/or sphincter abnormalities
  7. Subject with confirmed or suspected malignancy of the prostate or the bladder.
  8. Previous prostatic surgery.
  9. History of bladder stone, major hematuria, urethral stricture, bladder neck stenosis.
  10. Patient having a prosthesis in the procedure area
  11. Patient with an active anorectal disease
  12. Treatment emergency
  13. Individual unable to respect timing and visits determined by the protocol.
  14. Constitutional hemostasis and coagulation abnormalities not linked to oral medications
  15. Any disease or patient condition which can be a contra indication to his enrolment in the study, according to the investigator.

Sites / Locations

  • Hôpital TENON - Service d'Urologie

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

1 : TURP

2 : PVP

Arm Description

Surgery: TransUrethral Resection of the Prostate

Surgery: Photo selective Vaporization of the Prostate

Outcomes

Primary Outcome Measures

Hospital stay
Clinical symptoms at 1-yr follow-up evaluated with usual objective and subjective parameters

Secondary Outcome Measures

Rate of complication needing re-hospitalisation or reintervention
Risk of ignoring a localized prostate cancer needing a curative management.
Total and post-operative costs during follow-up.
Evaluation of side effects during follow-up.
Patient satisfaction
Evaluation of quality of life

Full Information

First Posted
December 21, 2009
Last Updated
April 30, 2013
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministry of Health, France, American Medical Systems
search

1. Study Identification

Unique Protocol Identification Number
NCT01043588
Brief Title
TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management
Acronym
REVAPRO
Official Title
Transurethral Resection of the Prostate With Photo Selective Vaporization of the Prostate Using the High Powered 532nm Laser Obstructive Benign Prostatic Hyperplasia Management: Focus on Efficiency and Cost-effectiveness
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
February 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministry of Health, France, American Medical Systems

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to compare medical efficacy and cost effectiveness of two surgical options for obstructive BPH management : transurethral resection of the prostate with photo selective vaporization of the prostate using the high powered 532nm laser.
Detailed Description
The aim of this study is to compare medical efficacy and cost effectiveness of two surgical options for obstructive BPH management : transurethral resection of the prostate with photo selective vaporization of the prostate using the high powered 532nm laser. Patients were randomized in two groups after inclusion. Perioperative data were collected, and follow-up was conducted for one month.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Benign Prostatic Hyperplasia
Keywords
Surgery, Prostate, Laser 532 nm, Photo selective Vaporization of the Prostate (PVP), TransUrethral Resection of the Prostate (TURP), Men health

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
142 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1 : TURP
Arm Type
Other
Arm Description
Surgery: TransUrethral Resection of the Prostate
Arm Title
2 : PVP
Arm Type
Other
Arm Description
Surgery: Photo selective Vaporization of the Prostate
Intervention Type
Procedure
Intervention Name(s)
TURP
Intervention Description
TransUrethral Resection of the Prostate
Intervention Type
Procedure
Intervention Name(s)
PVP
Intervention Description
Photo selective Vaporization of the Prostate
Primary Outcome Measure Information:
Title
Hospital stay
Time Frame
end of hospitalization
Title
Clinical symptoms at 1-yr follow-up evaluated with usual objective and subjective parameters
Time Frame
at one year
Secondary Outcome Measure Information:
Title
Rate of complication needing re-hospitalisation or reintervention
Time Frame
from the surgical procedure until one year follow-up
Title
Risk of ignoring a localized prostate cancer needing a curative management.
Time Frame
at one year
Title
Total and post-operative costs during follow-up.
Time Frame
from the surgical procedure until one year follow-up
Title
Evaluation of side effects during follow-up.
Time Frame
from the surgical procedure until one year follow-up
Title
Patient satisfaction
Time Frame
during follow up
Title
Evaluation of quality of life
Time Frame
during follow up

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male, 50 years of age or older. American Society of Anesthesiology (ASA) classification of physical status, class 1-3 Signed an informed consent at the beginning of the study. Patients presenting with LUTS associated to benign prostatic enlargement for more than 3 months, needing a surgical management, with at least one of the following situations: disability score ≥3, I-PSS ≥12, or full urinary retention Qmax ≤12ml /s for no drained patients with voided volume> 125 ml. Estimated prostate weight between 25g and 80g Patient free of catheter with PVR ≤ 300cc Patient without renal disorders. No prostate cancer suspicion at clinical examination, including DRE. PSA ≤ 10 ng/ml, with negative prostate biopsies of PSA is between 4 and 10 ng/mL if patient is 75 years or younger or has a life expectancy of more than 10 years. In case of anticoagulation or anti-aggregation therapy, necessary preoperative visit by anaesthesiologist to determine the supply therapy around surgery. In case of current BPH medical management, alpha blockers and herbal medicines should be stopped one week before surgery and 5-alpha-reductase-inhibitors should be stopped one month before surgery. Patient must be affiliated to the French social healthcare or equivalent Exclusion Criteria: Uncontrolled cardiopulmonary disorder, previously or recently diagnosed by standard methods Assessed sphincter detrusor dyssynergia, or myasthenia, multiple sclerosis, or Parkinson disease. History of pelvic lesions with abdominal sphincter injury. Urinary tract infection without antibiotics. Patient with urinary catheter or suprapubic catheter because of an acute urinary retention linked to an alternative diagnosis or impaired bladder sensation. Subject with neurogenic bladder and/or sphincter abnormalities Subject with confirmed or suspected malignancy of the prostate or the bladder. Previous prostatic surgery. History of bladder stone, major hematuria, urethral stricture, bladder neck stenosis. Patient having a prosthesis in the procedure area Patient with an active anorectal disease Treatment emergency Individual unable to respect timing and visits determined by the protocol. Constitutional hemostasis and coagulation abnormalities not linked to oral medications Any disease or patient condition which can be a contra indication to his enrolment in the study, according to the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bertrand LUKACS, MD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital TENON - Service d'Urologie
City
Paris
ZIP/Postal Code
75020
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
16126327
Citation
Bachmann A, Schurch L, Ruszat R, Wyler SF, Seifert HH, Muller A, Lehmann K, Sulser T. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005 Dec;48(6):965-71; discussion 972. doi: 10.1016/j.eururo.2005.07.001. Epub 2005 Jul 18.
Results Reference
background
PubMed Identifier
22341632
Citation
Lukacs B, Loeffler J, Bruyere F, Blanchet P, Gelet A, Coloby P, De la Taille A, Lemaire P, Baron JC, Cornu JN, Aout M, Rousseau H, Vicaut E; REVAPRO Study Group. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol. 2012 Jun;61(6):1165-73. doi: 10.1016/j.eururo.2012.01.052. Epub 2012 Feb 8.
Results Reference
derived

Learn more about this trial

TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management

We'll reach out to this number within 24 hrs